Ken Griffin Caribou Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 42,800 shares of CRBU stock, worth $58,636. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,800
Previous 18,000
137.78%
Holding current value
$58,636
Previous $29,000
186.21%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CRBU
# of Institutions
136Shares Held
52.6MCall Options Held
148KPut Options Held
70.7K-
Black Rock Inc. New York, NY6.95MShares$9.52 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.62MShares$6.33 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC4.57MShares$6.26 Million0.0% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA4.31MShares$5.9 Million0.49% of portfolio
-
Kynam Capital Management, LP Princeton, NJ2.36MShares$3.23 Million0.38% of portfolio
About Caribou Biosciences, Inc.
- Ticker CRBU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,840,800
- Market Cap $83.4M
- Description
- Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...